Zejula

Chemical Nameniraparib
Dosage FormCapsule (oral; 100 mg)
Drug ClassInhibitors
SystemFemale reproductive
CompanyGlaxoSmithKline plc
Approval Year2017

Indication

  • To maintain treatment of recurrent epithelial ovarian cancer in complete or partial response to platinum-based chemotherapy in adults.
  • To maintain treatment of fallopian tube cancer in complete or partial response to platinum-based chemotherapy in adults.
  • To maintain treatment of primary peritoneal cancer in complete or partial response to platinum-based chemotherapy in adults.
  • To treat advanced ovarian cancer associated with homologous recombination deficiency in adults who have been treated with three or more prior chemotherapy regimens.
  • To treat advanced fallopian tube cancer associated with homologous recombination deficiency in adults who have been treated with three or more prior chemotherapy regimens.
  • To treat advanced primary peritoneal cancer associated with homologous recombination deficiency in adults who have been treated with three or more prior chemotherapy regimens.
Last updated on 11/6/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zejula (Niraparib) Prescribing Information 2017GlaxoSmithKline, Research Triangle Park, NC
Document TitleYearSource
PARP inhibitors in the management of ovarian cancer: ASCO guideline. 2020Journal of Clinical Oncology